Hint mode is switched on Switch off
For swift navigation between sections

YD Bio

PDF download

Choose all Reset all
Download Cancel
Organization name
YD Bio Ltd
Country name
USA
Country of registration
Cayman Islands
Industry
Medical Services
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

YD Bio Ltd is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, and innovative therapies, especially in oncology and ophthalmology. The company emphasizes DNA methylation-based cancer detection, including tests for pancreatic cancer screening and breast cancer recurrence monitoring. It also develops stem cell- and exosome-based therapies for eye diseases through partnerships, such as with 3D Global Biotech. Additionally, YD Bio provides support services for clinical trials and has recently become publicly traded on Nasdaq via a business combination with Breeze Holdings Acquisition Corp, securing over $11.5 million in funding to accelerate innovation and growth.

Awards

Documentation

IFRS/US GAAP reports

2025
IV q eng
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    8071 SERVICES-MEDICAL LABORATORIES
  • CIK
    0002011674
Registration is required to get access.